|
|
Post by lakers on Nov 10, 2016 0:53:50 GMT -5
|
|
|
|
Post by liane on Nov 10, 2016 5:03:46 GMT -5
Please go to the link to see the full transcript.
|
|
|
|
Post by dejude42 on Nov 10, 2016 8:33:34 GMT -5
please check site malicious software attack or overload? can not type message did you post transcript site thank you for all you do
|
|
|
|
Post by lakers on Nov 10, 2016 11:34:56 GMT -5
Notable excerpts.
We confirmed Afrezza as promotionally sensitive and planned to expand our sales efforts to grow sales more quickly, more we believe will have an impact. We also plan to expand our targeted direct-to-consumer advertising to now include television.
We continue to have success in our partnerships with payors such as our contract with Express Scripts, which covers approximately 50 million lives on commercial and Medicare Part D and now been covered with no further authorizations required.
we have filed in our discussions with FDA regarding an improvement to the Afrezza label, we will keep you informed as this develops. At the same time, we are investing in our future clinically not only by starting our pediatric clinical studies in Q1, but also additional studies to better demonstrate the advantages of Afrezza, Afrezza’s PK and PD profile by focusing our near-term investment in the starting and titrating the product quickly and effectively with CGM and/or standardized dose titration schedules.
We are also making progress with our inhaled epinephrine program. We will be meeting with the FDA next month to agree on the path forward to approval, we will have a lot more news once that has been accomplished. We think the time is right for simple and affordable alternatives in the FB market.
We also continue to make progress on our receptor life sciences collaboration and we’ll achieve certain predetermined tactical objectives later this month. [This will trigger RLS milestone payments 4Q16]
|
|
